Power of Precise Patient Selection
Appropriate patient selection is critical to the success of Zephyr® Valve treatment. Over time, clinical trial data have helped define the successful patient profile.1-4,6,7 The Zephyr Valve is the first endobronchial valve to receive approval from the FDA for patients with either heterogeneous and homogeneous emphysema and can be used to treat the upper and lower lobes of either lung.
COPD Clinical Workup
Zephyr Valve candidates are evaluated with standard clinical work-up.
- FEV1 <45% predicted and >15% predicted
- Heterogeneous or homogeneous emphysema
- Upper or lower lobe
- Symptomatic despite optimal medication
Lobe Treatment Planning Support with StratX®
StratX Lung Analysis Platform:
- Cloud-based quantitative CT analysis service
- Provides information on emphysema destruction, fissure completeness, and lobar volume
- Helps identify target lobes for Zephyr Valve treatment
Patients with >80% fissure completeness scores are likely to have negative collateral ventilation (CV-) and could be a candidate for Zephyr Valves
Chartis® Assesses Collateral Ventilation
The Chartis Pulmonary Assessment System:
- Proprietary balloon catheter and console with flow and pressure sensors
- Used to assess the presence of collateral ventilation (CV) within isolated lobes of the lung, which is a predictor of response to treatment
- Provides precise flow and pressure readings for specific lobes in the lung at the lobar level
Zephyr® Valves Placed
In qualifying patients, Zephyr Valves are then placed in a minimally invasive procedure.
- 30-60 minute procedure
- Typically, 3 to 5 valves placed to completely occlude the lobe
- Zephyr Valves can be removed or retracted through bronchoscope
- 3-night stay in the hospital
Assess with Certainty. Treat with Confidence.
Used prior to placement of valves, StratX and Chartis give physicians confidence in their treatment decision and are a critical addition to analysis of fissure completeness. Without Chartis, physicians may treat a lobe that has collateral ventilation, or unnecessarily rule out a patient who could have benefitted.
Patient Selection Benefit Of Chartis7
*Includes patients with “low plateau” measurements, typically not achieving TLVR when treated
**Includes patients with “low flow” readings in the target lobe, typically resulting in TLVR when treated
Patient Treatment Preference
A detailed survey of 294 severe emphysema patients evaluated how they balance potential risks and benefits. The study concluded that patients with severe emphysema value access to an interventional treatment that offers benefits above and beyond their current medical management, despite the risks associated with these treatments.8
More Than 3 in 4 Patients Would Select a Treatment with the Clinical Benefits and Risk Profile of the Zephyr Valve Over Current Treatment.8
Clinical Spotlights
The LIBERATE Study
A multicenter, multinational randomized controlled trial of Zephyr® Endobronchial Valves in patients with heterogenous emphysema and little to no collateral ventilation.
The TRANSFORM Study
A multicenter, multinational randomized controlled trial of Zephyr® Endobronchial Valves in patients with heterogenous emphysema and little to no collateral ventilation.
The IMPACT Study
A multicenter, multinational randomized controlled trial of Zephyr® Endobronchial Valves in patients with heterogenous emphysema and little to no collateral ventilation.
The STELVIO Study
A multicenter, multinational randomized controlled trial of Zephyr® Endobronchial Valves in patients with heterogenous emphysema and little to no collateral ventilation.
Patient Stories
Lance’s Story
Age at Treatment: 64
Fairfax, Virginia
My message to everyone suffering with COPD and emphysema is if you qualify for the valves, go for it! It’s been a miracle for me. It has made a huge difference in the quality of my life and my kids’ lives. They aren’t worrying about me constantly anymore. I am not cured, but I am living again!
Charlie’s Story
Age at Treatment: 68
Fairfax, Virginia
My story about this procedure tells people what life can be even with COPD. It really brought me back. I am a walking Christmas present. This far exceeded my expectations!
Karen’s Story
Age at Treatment: 62
Melbourne, FL
I want to share my story because there are a lot of people who can benefit from these valves. For many of us, it’s the difference between living and just surviving.
Flo’s Story
Age at Treatment: 63
Texas City, TX
I feel strongly that part of my new path in life is to help spread the word about the Zephyr Valves so other sufferers can learn about this option and have hope. I will be attending local breathing club meetings and sharing my story online.
Jim’s Story
Age at Treatment: 76
Albany, NY
I was excited to share my story to give others hope and make sure they know that there is another option now that can help you get your life back.
Nancy’s Story
Age at Treatment: 69
Grand Rapids, MI
“If I didn’t happen to see that news story, I would not have known about this procedure so I am happy to share my story so others can be aware of this.”
John’s Story
Age at Treatment: 78
Chicago, IL
“I haven’t felt this good since my 50s. It’s like getting a new lease on life.”
Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.